All Immuno-oncology articles – Page 7
-
NewsGround-breaking glycocalyx study could improve cancer immunotherapy
The researchers found that cancer cells with thicker glycocalyx barrier are better at evading immune cells.
-
Whitepaper
Whitepaper: Serum-free and Animal-free Research
Discover how the adoption of animal-free media/supplements can improve reproducibility in cell culture and biotherapeutic research.
-
WhitepaperWhitepaper: PSMA Protein in the Battle Against Cancer
The PSMA Protein is a new therapeutic hot target. In this article, learn about its growing role in the fight against prostate cancer and beyond.
-
NewsStopping immune cell leakage from tumours could improve skin cancer treatment
Results show the number of specialised immune cells available for fighting skin cancer doubled when a new treatment blocked their escape from melanoma tumours.
-
ArticleTransforming the way cancer vaccines are designed and made
Researchers found that ‘rational vaccinology’ increases potency by changing the structural location of antigens and adjuvants.
-
NewsDiscovery of CAFs’ origin gives new direction for pancreatic cancer
US researchers discovered a type of cell involved it pancreatic cancer and sheds light on the origin of cancer-associated fibroblasts (CAFs).
-
ArticleDeveloping state-of‑the‑art CAR T-cell therapy for cancer treatment
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
-
ArticleAllogeneic CAR T-cell therapy: the future of cancer care
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
-
Article
The next wave: going beyond CAR T cells with cell-based therapies
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
-
Article
The advantages of gamma-delta T-cell therapy
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
-
ArticleWhen exhausted, cancer-fighting T cells may switch sides
Using flow cytometry, Dr Greg Delgoffe and Dr Paolo Vignali highlight that low oxygen environment of tumours can prompt exhausted T cells to suppress the immune system instead of combating cancer.